Evidence map›Paper›PMID 40595713›Full record

ArticleScientific reports2025

Exploring the interconnected properties of cannabidiol suspensions and orodispersible films.

Robert-Alexandru Vlad, Andrada Pintea, Paula Antonoaea, Emöke-Margit Rédai, Magdalena Bîrsan, Gabriel Hancu, Lénárd Farczádi, Silvia Imre, Daniela-Lucia Muntean, Tamás Sovány and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Robert-Alexandru VladPharmaceutical Technology and Cosmetology Department, Faculty of Pharmacy, "George Emil Palade", University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, 38 Gheorghe Marinescu Street, Târgu Mureș, 540142, Romania.
Andrada PinteaPharmaceutical Technology and Cosmetology Department, Faculty of Pharmacy, "George Emil Palade", University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, 38 Gheorghe Marinescu Street, Târgu Mureș, 540142, Romania.
Paula AntonoaeaPharmaceutical Technology and Cosmetology Department, Faculty of Pharmacy, "George Emil Palade", University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, 38 Gheorghe Marinescu Street, Târgu Mureș, 540142, Romania. paula.antonoaea@umfst.ro.
Emöke-Margit RédaiPharmaceutical Technology and Cosmetology Department, Faculty of Pharmacy, "George Emil Palade", University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, 38 Gheorghe Marinescu Street, Târgu Mureș, 540142, Romania.
Magdalena BîrsanDrug Industry and Pharmaceutical Biotechnology Department, Faculty of Pharmacy, "Grigore T. Popa", University of Medicine and Pharmacy from Iași, 16 Universităţii Street, 700115, Iași, Romania.
Gabriel HancuPharmaceutical and Therapeutic Chemistry Department, Faculty of Pharmacy, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, 38 Gheorghe Marinescu Street, Târgu Mureș, 540142, Romania.
Lénárd FarczádiChromatography and Mass Spectrometry Laboratory, Centre for Advanced Medical and Pharmaceutical Research, "George Emil Palade" University of Medicine, Pharmacy, Sciences and Technology of Târgu Mureș, 38 Gheorghe Marinescu Street, Târgu Mureș, 540142, Romania.
Silvia ImreChromatography and Mass Spectrometry Laboratory, Centre for Advanced Medical and Pharmaceutical Research, "George Emil Palade" University of Medicine, Pharmacy, Sciences and Technology of Târgu Mureș, 38 Gheorghe Marinescu Street, Târgu Mureș, 540142, Romania.
Daniela-Lucia MunteanAnalytical Chemistry and Drug Analysis Department, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, Târgu Mureș, 540142, Romania.
Tamás SoványInstitute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Eötvös Street, Szeged, 6720, Hungary.
Katalin KristóInstitute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Eötvös Street, Szeged, 6720, Hungary.
Krisztina LudasiInstitute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Eötvös Street, Szeged, 6720, Hungary.
Géza RegdonInstitute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Eötvös Street, Szeged, 6720, Hungary.
Adriana CiurbaPharmaceutical Technology and Cosmetology Department, Faculty of Pharmacy, "George Emil Palade", University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, 38 Gheorghe Marinescu Street, Târgu Mureș, 540142, Romania.

Funding

"George Emil Palade" University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, Romania 164/27/10.01.2023
6 · The paper itself

Abstract

In this study, orodispersible films (ODFs) were developed as fast-releasing formulations for pediatric patients suffering from Lennox-Gastaut or Dravet syndrome, with cannabidiol (CBD) selected as the active pharmaceutical ingredient (API). The properties of the ODFs were evaluated both before and after casting, with a focus on establishing a correlation between the properties of colloidal dispersion/suspension and ODFs to enhance understanding of the manufacturing process. Two blank colloidal dispersions were characterized for spreadability, viscosity, tangential stress, and pH, and their properties were correlated with those of blank ODFs, including mass uniformity, thickness, folding endurance, thickness-normalized crushing strength, disintegration time (evaluated through two different methods) and adhesivity. The strength and direction of the correlation were established via the Pearson coefficient. The same statistical approach was applied to assess correlation between CBD suspension (DCBD1, DCBD2) properties and CBD-ODF parameters. For the suspensions, particle size evaluation was also considered. Although few statistically significant positive or negative correlations were observed, a notable finding of this study was the dissolution behavior of CBD-ODF2, where nearly 100% of the API was released at 30 min, which is consistent with the disintegration behavior evaluated through the pharmacopeial method. Notably, CBD is classified as a Biopharmaceutical Classification System (BCS) Class II compound.

Indexed as

CannabidiolAdministration, OralDrug CompoundingDrug LiberationEpilepsies, MyoclonicHumansParticle SizeSolubilitySuspensionsViscosityCannabidiolSuspensionsColloidal dispersionsCorrelation coefficientsDissolution behaviorPolymeric films

Identifiers

PMID40595713
PMCPMC12215374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.